Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 5/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24317253 | 0.86 | SLC6A4 (0.43) | SLC6A4SLC6A3SLC6A2SLC5A2ABCB11 | |
| SCHEMBL23940689 | 0.82 | SLC6A2 (0.34) | SLC6A4SLC6A3SLC6A2SLC5A2SLC5A1 | |
| SCHEMBL23940705 | 0.81 | SLC6A2 (0.34) | SLC6A4SLC6A3SLC6A2SLC5A2CYP3A4 | |
| SCHEMBL20007142 | 0.77 | SLC6A2 (0.42) | SLC6A4SLC6A3SLC6A2CYP3A4CYP2C9 | |
| SCHEMBL18255229 | 0.76 | SLC6A2 (0.41) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL18255228 | 0.76 | SLC6A2 (0.41) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL18255230 | 0.76 | SLC6A2 (0.41) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL18255254 | 0.76 | SLC6A2 (0.41) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL18255226 | 0.76 | SLC6A2 (0.41) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL18959855 | 0.75 | PTGS1 (0.40) | SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141926-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2018-05-24 | — | — | US | disclosed |
| EP-3299364-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | Zhejiang Ausun Pharmaceutical Co., Ltd. (CN) | 2018-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141926-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | CYP4A11, CYP11B2, ADRB1 | SLC6A4 440/4885SLC6A3 775/4885SLC6A2 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.